Diagnosis, Prognosis and Clinical Trial in Crimean-Congo Hemorrhagic Fever

Büyüktuna, Seyit Ali; Doğan, Halef Okan

doi:10.1007/978-3-030-71165-8_11

Cited by 3 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, it highlights the need to develop new biomarkers to help diagnose CCHFV. Platelets, AST, ALT, first-step coagulation assays, LDH creatinine, and fibrinogen have all been identified as laboratory indications of CCHFV [68][69][70]. After the acute phase of the infection, which lasts 4-9 days after symptoms appear, active CCHFV infection may be identified by IgM or a substantial rise in IgG titer; however, severe and fatal cases often do not develop a detectable Ab response.…”

Section: Standard Molecular Detectionmentioning

confidence: 99%

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Muzammil,

Rayyani,

Abbas Sahib

et al. 2024

Biol Proced Online

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus, and zoonosis, and affects large regions of Asia, Southwestern and Southeastern Europe, and Africa. CCHFV can produce symptoms, including no specific clinical symptoms, mild to severe clinical symptoms, or deadly infections. Virus isolation attempts, antigen-capture enzyme-linked immunosorbent assay (ELISA), and reverse transcription polymerase chain reaction (RT-PCR) are all possible diagnostic tests for CCHFV. Furthermore, an efficient, quick, and cheap technology, including biosensors, must be designed and developed to detect CCHFV. The goal of this article is to offer an overview of modern laboratory tests available as well as other innovative detection methods such as biosensors for CCHFV, as well as the benefits and limits of the assays. Furthermore, confirmed cases of CCHF are managed with symptomatic assistance and general supportive care. This study examined the various treatment modalities, as well as their respective limitations and developments, including immunotherapy and antivirals. Recent biotechnology advancements and the availability of suitable animal models have accelerated the development of CCHF vaccines by a substantial margin. We examined a range of potential vaccines for CCHF in this research, comprising nucleic acid, viral particles, inactivated, and multi-epitope vaccines, as well as the present obstacles and developments in this field. Thus, the purpose of this review is to present a comprehensive summary of the endeavors dedicated to advancing various diagnostic, therapeutic, and preventive strategies for CCHF infection in anticipation of forthcoming hazards. Graphical Abstract

show abstract

Section: Standard Molecular Detectionmentioning

confidence: 99%

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Muzammil,

Rayyani,

Abbas Sahib

et al. 2024

Biol Proced Online

View full text Add to dashboard Cite

show abstract

Acute promyelocytic leukemia as a differential diagnosis of Crimean-Congo hemorrhagic fever

Beheshti,

Yazdani,

Salehi-Vaziri

et al. 2024

Future Virology

View full text Add to dashboard Cite

Assessment of Serum Beta 2-Microglobulin Levels in Crimean-Congo Hemorrhagic Fever Patients: Implications for Immune Activation and Disease Pathogenesis

Buyuktuna,

Bolat,

Doğan

et al. 2024

Cumhuriyet Science Journal

View full text Add to dashboard Cite

Crimean-Congo Hemorrhagic Fever (CCHF) presents a spectrum of clinical manifestations, ranging from asymptomatic cases to severe, life-threatening conditions. Despite extensive research on CCHF pathogenesis, comprehensive understanding remains elusive. Our investigation focused on assessing serum beta 2-microglobulin (β2M) levels in CCHF patients, aiming to elucidate its potential as an immune activation marker and its involvement in disease pathogenesis. The study enrolled 45 CCHF patients and 45 healthy volunteers as a control group. Serum β2M levels were quantified using the immunoturbidimetric analysis method. The patient group was divided into two groups, mild and moderate-severe, using scoring systems. The mean β2M values for the control, mild, and moderate-severe patient groups were 2.27±0.50, 4.37±1.29, and 5.82±2.62 mg/L, respectively (p<0.001). Positive correlations were noted between β2M concentrations and markers such as BUN, creatinine, uric acid, creatine kinase, and aPTT (p<0.001, r=0.684; p<0.001, r=0.602; p=0.003, r=0.439; p=0.008, r=0.392; p=0.019, r=0.348, respectively). Conversely, negative correlations were observed with total protein, albumin, and platelet count (p=0.021, r=-0.342; p=0.003, r=-0.434; p=0.048, r=-0.296, respectively). The findings suggest a prominent inflammatory response in CCHF, indicated by elevated β2M levels, implying its potential role in the molecular mechanisms of the disease

show abstract

Diagnosis, Prognosis and Clinical Trial in Crimean-Congo Hemorrhagic Fever

Cited by 3 publications

References 56 publications

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges

Acute promyelocytic leukemia as a differential diagnosis of Crimean-Congo hemorrhagic fever

Assessment of Serum Beta 2-Microglobulin Levels in Crimean-Congo Hemorrhagic Fever Patients: Implications for Immune Activation and Disease Pathogenesis

Contact Info

Product

Resources

About